A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma

A Study Using 18F-FAPI PET to Evaluate Pathologic Response to Systemic Treatment in Pancreatic Adenocarcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06277206

Enrollment

Registered

2024-02-26

Start date

2021-08-04

Completion date

2024-02-10

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

18F-FAPI, Pancreas Adenocarcinoma, Pathologic Response, Systemic Treatment

Brief summary

To explore the potential utility of 18F-FAPI-04 PET/CT for pathologic response evaluation to systemic treatment in PDAC

Interventions

DIAGNOSTIC_TEST18F-FAPI PET/CT

Enrolled patients underwent 18F-FAPI PET/CT at diagnosis. And preoperative 18F-FAPI PET/CT was completed in the patients met the criteria for conversion surgery after systemic treatment. The correlation between changes of parameters before and after treatment and pathologic response was analyzed.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* suspected to have pancreatic cancer by radiological imaging * planned systemic treatment * possibility of conversion surgery * willingness to participate the study

Exclusion criteria

* without pathologically confirmed pancreatic cancer * poor performance status or organ functions that cannot meet the systemic treatment requirements * metastatic disease * pregnant patients

Design outcomes

Primary

Measure	Time frame	Description
Change of Maximum standardized uptake value	Baseline and preoperation	Change of SUVmax before and after treatment
Change of Mean standardized uptake value	Baseline and preoperation	Change of SUVmean before and after treatment

Secondary

Measure	Time frame	Description
Metabolic Tumor Volume	Baseline	Baseline MTV at diagnosis
Total Lesion FAP expression	Baseline	Baseline TLF at diagnosis
Maximum standardized uptake value	Baseline	Baseline SUVmax at diagnosis
Change of Total Lesion FAP expression	Baseline and preoperation	Change of TLF before and after treatment
Change of Metabolic Tumor Volume	Baseline and preoperation	Change of MTV before and after treatment
Mean standardized uptake value	Baseline	Baseline SUVmean at diagnosis

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026